Granules India

₹800.55As of Sun 8 Nov 2026, 12:00 UTC
NSE:GRANULESHealthcare
Country India
PE (Fwd) 27.70
TSR 10Y CAGR 21.21%
Div yield 0.22%
ROE —
Drug Manufacturers (Specialty & Generic)
Beta (5Y) 0.12
PE TTM 32.73
TSR TTM 41.83%
Mkt cap ₹197.0B
ROIC —
SE Grade™
Value
Quality
Moat
1Y Price
Reference
₹889
11.04%
(62.08%)
Price above Reference Value
FY23
FY24
FY25
FY26
Earnings per share₹
21.00
16.72
20.68
24.46
26.51%
(20.38%)
23.68%
18.28%
Revenue₹B
45.12
45.06
44.82
53.66
19.84%
(0.12%)
(0.55%)
19.73%
TTM
FYE 31 Mar INR
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
FY2026
FY2027E
Trend
5Y
10Y
Peers
53.66
Revenue₹B
—
—
—
—
—
37.65
45.12
45.06
44.82
53.66
58.46
9.26%
9.26%
50
19.73
Revenue growth%
—
—
—
—
—
—
19.84
(0.12)
(0.55)
19.73
8.95
9.80
—
93
61.66
Gross margin%
—
—
—
—
—
47.74
46.98
52.72
58.58
61.66
61.63
52.72
52.72
60
16.63
Operating margin%
—
—
—
—
—
15.27
16.35
14.49
16.12
16.63
16.66
16.12
16.12
60
11.09
Net margin%
—
—
—
—
—
10.96
11.45
8.99
11.19
11.09
11.10
11.09
11.09
57
32.73
P/E ratio (avg)x
—
—
—
—
—
20.00
14.95
21.57
27.18
21.79
30.00
21.57
21.57
32
21.83
EV/EBITx
—
—
—
—
—
14.36
10.47
13.39
18.87
14.53
20.00
14.36
14.36
37
—
FCF yield (avg)%
—
—
—
—
—
—
—
—
—
—
—
—
—
20
—
FCF margin%
—
—
—
—
—
—
—
—
—
—
—
—
—
27
—
FCF / Net incomex
—
—
—
—
—
—
—
—
—
—
—
—
—
16
—
ROIC%
—
—
—
—
—
—
—
—
—
—
—
—
—
67
—
Return on equity%
—
—
—
—
—
—
—
—
—
—
—
—
—
66
—
Return on assets%
—
—
—
—
—
—
—
—
—
—
—
—
—
77
24.46
EPS₹
—
—
—
—
—
16.60
21.02
16.72
20.68
24.46
26.69
10.17%
10.17%
—
18.28
EPS growth%
—
—
—
—
—
—
26.62
(20.44)
23.66
18.28
9.10
20.97
—
74
—
Bookvalue per sh₹
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
FCF per share₹
—
—
—
—
—
—
—
—
—
—
—
—
—
—
1.75
Dividend per sh₹
—
—
—
—
—
1.50
1.50
1.50
1.50
1.75
1.83
3.93%
3.93%
—
0.22
Div yield (avg)%
—
—
—
—
—
0.45
0.48
0.42
0.27
0.33
0.23
0.42
0.42
4
7.15
Payout ratio%
—
—
—
—
—
9.04
7.14
8.97
7.25
7.15
6.86
7.25
7.25
8
243.2
Shares (diluted)M
—
—
—
—
—
248.6
245.7
242.3
242.5
243.2
◌243.2
(0.54%)
(0.54%)
14
(0.31)
Buyback yield%
—
—
—
—
—
—
1.15
1.38
(0.06)
(0.31)
◌—
0.55
—
14
—
D/E ratiox
—
—
—
—
—
—
—
—
—
—
—
—
—
66
194.7
Enterprise value₹B
—
—
—
—
—
82.56
77.25
87.43
136.3
129.6
194.7
11.94%
11.94%
43
—
LT debt₹M
—
—
—
—
—
—
—
—
—
—
—
—
—
30
Peers (US$2.100B)
Cap (US$)
PE
Capital
TTM
5Y
10Y
Leveragex
—
—
—
EBIT/Intx
12.49
12.49
12.49
Own earn%
—
—
—
Sh yield%
(0.09)
0.92
0.92
Owners
Insiders/Inst%
40.90
24.04
Short interest%
—
SBC / revenue%
—
Record
10Y
Profitable years
5/5
Revenue growth years
2/4
EPS growth years
3/4
Dividend streakyrs
0
Op margin range%
14–17
$1 testx
—
Incr. ROIC%
—

Granules India Limited manufactures and sells active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates (PFIs), finished dosages (FDs), and peptides CDMO in India and internationally. It offers paracetamol, metformin, guaifenesin, ibuprofen, and methocarbamol, as well as prescription and over-the-counter products.

Growth vs revenue
Latest
Trend
4Y CAGR
Rel growth
Revenue
₹53.66B
9.26%
1.00×
Cost of revenue
₹20.57B
1.12%
0.73×
Operating expenses
₹24.16B
18.57%
1.39×
Revenue by region
No breakdown available
Reinvestment returns
n/m
Trend
Reinvestment rate
n/m
-
Return on capital
n/m
-
Spread over hurdle
n/m
-